RxDoctor Payments Data

Donald Chipman, MD

Pain Medicine · Crestview, FLNPI 1740287564

Payments from drug & device makers

$1,264in general payments, 2019–2025

Across 47 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$860
  • Nevro Corp.$175
  • Relievant Medsystems, Inc.$49
  • Kowa Pharmaceuticals America, Inc.$28
  • Biodelivery Sciences International, Inc.$28
  • Si-bone, Inc.$28
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$1,258100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,264 in reported general payments places this provider in the 40th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$534,586
Medicare patients
1,287
Services billed
11,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,887$77,801
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,546$50,091
MovantikNaloxegol Oxalate60$24,909
Gabapentin1,057$14,201
BelbucaBuprenorphine Hcl27$13,783
LinzessLinaclotide19$13,724
OxycontinOxycodone Hcl14$13,176
Buprenorphine69$11,432
Tramadol Hcl ErTramadol Hcl153$11,374
Fentanyl117$11,125
Pregabalin531$10,090
Lidocaine69$9,390
Oxycodone Hcl443$7,308
Morphine Sulfate ErMorphine Sulfate157$7,224
Tramadol Hcl577$6,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$18$18,14839 claims
AbbVieLinzess$18$13,72419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →